4//SEC Filing
Alspaugh Jonathan 4
Accession 0001209191-21-052272
CIK 0001636282other
Filed
Aug 17, 8:00 PM ET
Accepted
Aug 18, 5:21 PM ET
Size
8.7 KB
Accession
0001209191-21-052272
Insider Transaction Report
Form 4
Alspaugh Jonathan
Chief Financial Officer
Transactions
- Purchase
Common Stock
2021-08-17$6.50/sh+23,392$151,985→ 33,172 total - Purchase
Common Stock
2021-08-16$6.37/sh+9,780$62,275→ 9,780 total - Purchase
Common Stock
2021-08-18$6.72/sh+7,200$48,400→ 40,372 total
Footnotes (3)
- [F1]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.13 to $6.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
- [F2]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.6 per share, inclusive.
- [F3]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.69 to $6.77 per share, inclusive.
Documents
Issuer
Aeglea BioTherapeutics, Inc.
CIK 0001636282
Entity typeother
Related Parties
1- filerCIK 0001868112
Filing Metadata
- Form type
- 4
- Filed
- Aug 17, 8:00 PM ET
- Accepted
- Aug 18, 5:21 PM ET
- Size
- 8.7 KB